{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:28:15Z","timestamp":1773386895270,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.tranon.2022.101523","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T23:14:22Z","timestamp":1662074062000},"page":"101523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?"],"prefix":"10.1016","volume":"25","author":[{"given":"Anjali","family":"Bhatt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-3559","authenticated-orcid":false,"given":"Kerrington","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.tranon.2022.101523_bib0001","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.tranon.2022.101523_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23147542","article-title":"New frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes","volume":"23","author":"Gallazzi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2022.101523_bib0003","series-title":"FDA Approves Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia","year":"2022"},{"key":"10.1016\/j.tranon.2022.101523_bib0004","series-title":"Genentech Announces Venclexta Combination Improved Overall Survival in People with Previously Untreated Acute Myeloid Leukemia","year":"2022"},{"issue":"7","key":"10.1016\/j.tranon.2022.101523_bib0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.tranon.2022.101523_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.8084","article-title":"Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review","volume":"4","author":"Mohyuddin","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"26","key":"10.1016\/j.tranon.2022.101523_bib0007","first-page":"2536","article-title":"Ivosidenib and azacitidine in IDH1-mutated AML","volume":"386","author":"Goodman","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.tranon.2022.101523_bib0008","first-page":"2536","article-title":"Ivosidenib and azacitidine in IDH1-mutated AML. Reply","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2022.101523_bib0009","series-title":"FDA Approves Venetoclax in Combination for AML in Adults","year":"2022"},{"key":"10.1016\/j.tranon.2022.101523_bib0010","unstructured":"FDA D.I.S.C.O. burst: tibsovo. U.S. food and drug administration. (Accessed 13 August), 2022, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-tibsovo-ivosidenib-combination-azacitidine-newly-diagnosed."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322001826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322001826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:26:04Z","timestamp":1761845164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523322001826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":10,"alternative-id":["S1936523322001826"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101523","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101523"}}